Arcutis Biotherapeutics (ARQT) Other financing activities (2019 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Other financing activities of $1.1 million for Q1 2026, up 170.13% year-over-year from $395000.0 in Q1 2025, and down 67.45% quarter-over-quarter from $3.3 million in Q4 2025.
Arcutis Biotherapeutics (ARQT) Other financing activities (2019 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Other financing activities history runs 8 years deep, the most recent figure standing at $1.1 million for Q1 2026.
- In Q1 2026, Other financing activities rose 170.13% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $5.3 million (up 160.07% YoY), while the FY2025 annual figure was $4.6 million, up 168.36% from the prior year.
- Other financing activities for Q1 2026 stood at $1.1 million, down from $3.3 million in the prior quarter.
- The five-year high for Other financing activities was $3.3 million in Q4 2025, with the low at $16000.0 in Q4 2022.
- The 5-year median for Other financing activities is $328000.0 (2022), against an average of $602500.0.
- The sharpest annual moves came in 2022 and 2023: Other financing activities slumped 96.13% in 2022, then soared 3512.5% in 2023.
- Arcutis Biotherapeutics' Other financing activities stood at $16000.0 in 2022, then soared by 1187.5% to $206000.0 in 2023, then soared by 416.5% to $1.1 million in 2024, then surged by 208.08% to $3.3 million in 2025, then tumbled by 67.45% to $1.1 million in 2026.
- Business Quant data shows ARQT's Other financing activities at $1.1 million in Q1 2026, $3.3 million in Q4 2025, and $863000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.36 Mn |
| Jun 30, 2026 | 1.36 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Mar 31, 2026 | 1.07 Mn |
| Dec 31, 2025 | 3.28 Mn |
| Dec 31, 2025 | 3.28 Mn |
| Sep 30, 2025 | 863,000.00 |
| Sep 30, 2025 | 863,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 61,000.00 |
| Mar 31, 2025 | 395,000.00 |
| Mar 31, 2025 | 395,000.00 |
| Dec 31, 2024 | 1.06 Mn |
| Dec 31, 2024 | 1.06 Mn |
| Jun 30, 2024 | 567,000.00 |
| Jun 30, 2024 | 567,000.00 |
| Mar 31, 2024 | 82,000.00 |
| Mar 31, 2024 | 82,000.00 |
| Dec 31, 2023 | 206,000.00 |
| Dec 31, 2023 | 206,000.00 |